PDR001-X2105 : Phase 1b, Multi-arm, Open-label Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

OnePhase One

18+Age Over 18

Blood<br/>CancersCancer LocationBlood
Cancers

Systemic therapy,Treatment | Blood / Myeloma / LymphomaAcute Myeloid Leukaemia,Myelodysplasia

Trial Overview Read MoreRead more

This is a phase I trial assessing the safety and tolerability of using immunotherapy drugs (PDR001 and /or MBG453) in combination with chemotherapy (Decitabine) to treat patients with Acute Myleoid Leukaemia or High Risk Myelodysplastic Syndrome.
 

This trial is treating patients with Acute Myeloid Leukaemia and Myelodysplasia.

This is a systemic therapy.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

Phase 1b, Multi-arm, Open-label Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Commercial Sponsor

Novartis Pharmaceuticals

Summary

This study aims to determine the safety, optimal regime and dose recommendations for two immunotherapy drugs (PDR001 and MBG453) in combination with Decitabine for the treatment of Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome. Patients eligible to participate in this study with be given a combination of PDR001 and/or MBG453 and/or decitabine.

Recruiting Hospitals Read MoreRead more

Alfred Hospital, Malignant Haematology & Stem Cell Transplantation Service
Prahran
Ms Nola Kennedy
n.kennedy@alfred.org.au
03 9076 2217

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next